| Name | Title | Contact Details |
|---|---|---|
Michael Miller |
Chief Technology Officer | Profile |
Were industry leader in driver risk management & insurance solutions, offering MVR & CSA monitoring, driver risk analysis & underwriting tools. Learn more!
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
We are a Deaf-owned company that provides video relay service and other communication solutions.
Palo Alto Software builds the worlds leading business plan, management and growth software. Were the makers of LivePlan and Business Plan Pro, as well as the experts behind Bplans a free resource for business planning.
Engageware is a company that provides customer engagement solutions for banks, credit unions, financial advisors, and retailers. Their solutions include consumer self-service, appointment scheduling, and knowledge management.